1. Different baseline rules, same goal
EU and FDA do not require the same paperwork, the same testing, or the same labels — but both aim to keep cosmetic products safe and properly described. The European Commission Regulation (EC) No 1223/2009 is a comprehensive, prescriptive framework: it defines who may sell a product, what documents must exist before sale, how ingredients are limited, and how a product is notified. FDA’s approach under the Federal Food, Drug, and Cosmetic Act is product-based rather than pre-approval based: cosmetics are not approved before sale, but they must be safe, correctly labeled and — since MoCRA was enacted in 2022 and is now phased in — supported by facility registration, product listing, safety substantiation and adverse-event reporting.
The practical impact: an EU listing requires formal documentation in place before launch, while a US listing can launch faster but is more exposed to follow-on compliance work (registration deadlines, safety-file readiness, adverse-event monitoring). Neither path is “easier” overall; they simply shift where the effort lands.
2. Side-by-side comparison
| Area | EU (EC 1223/2009) | USA (FDA / MoCRA) |
|---|---|---|
| Product approval | No pre-approval, but full documentation must exist before sale. | No pre-approval; products launch without FDA sign-off. |
| Responsible party | Responsible Person (RP) inside the EU. | Duty Holder; facility registration required. |
| Safety assessment | Cosmetic Product Safety Report (CPSR) with a qualified assessor. | Safety substantiation file; FDA does not pre-review it. |
| Notification | CPNP notification (via RP) before sale. | Facility registration + product listing; no pre-sale notification. |
| Ingredient rules | EU positive list, Annexes I-VI limits and restrictions. | FDA ingredient reviews; MoCRA banned-list expansion ongoing. |
| Colorants | Limited EU permitted colourants list. | FD&C approved colorants. |
| Allergen labeling | Allergen/fragrance labeling rules apply. | Ingredient list, no mandatory allergen call-outs. |
| Labelling (language) | Destination-country language required. | English labels required. |
| Stability / batch testing | Expected within CPSR framework. | Manufacturer-owned testing; no pre-sale review. |
| Adverse events | Reporting obligations apply. | MoCRA adverse-event reporting obligations apply. |
| Pricing driver | More front-loaded compliance cost. | More post-launch compliance cost. |
3. What this means for your launch plan
If you only sell in the US, you can move quicker to market but must budget for MoCRA-era duties: facility registration, product listing, a documented safety substantiation file and a process for adverse-event capture. If you only sell in the EU, you cannot sell without a Responsible Person, a completed CPSR, a CPNP notification and EU-compliant labels. If you sell in both, plan for two documentation tracks — this is the most common pattern for growing private label brands and the one ARIS is set up to support, because the same base formula can usually serve both markets with the right ingredient choices.
The single biggest planning decision is ingredient selection. A colourant, fragrance or preservative that is acceptable under FDA rules may be restricted or prohibited in the EU, and the reverse is true for some dyes. Choosing a palette and formula that avoids the most-restricted ingredients first is the fastest way to keep one formulation workable across both markets.
4. A two-market workflow that works
For a brand launching lip gloss, lipstick, lip balm or lip oil in both regions, the most reliable sequence is: (1) fix the destination markets before formula freeze; (2) build the formula against the EU restriction list where possible, since the EU list is generally more restrictive and therefore the safer default; (3) prepare two label sets — one in the EU destination language, one in English; (4) line up a Responsible Person for the EU and a US listing path; and (5) document safety substantiation for the US track. ARIS discusses the exact documentation scope and timeline in the RFQ, because the requirement set changes with market, category and launch date.
5. Common mistakes buyers make
The most frequent error is finalizing shade colourants before checking the destination lists — this forces rework once formulas are locked. The second is treating EU and US labels as interchangeable; they are not, and re-labeling after shipment is expensive. The third is launching to the EU without a confirmed Responsible Person and CPNP step, which blocks sale entirely. The fourth is assuming that a single safety dossier satisfies both regulators; each track has its own file. Plan each track separately from the first day and the rest of the launch runs cleaner.
Send ARIS your target markets, product categories and intended launch windows early. WhatsApp is the fastest way to start, and a full RFQ is available once your category, market and quantity direction are clear.
Do I need a Responsible Person to sell cosmetics in the EU?
Yes. EU cosmetics require a Responsible Person established in the EU who completes the CPNP notification before the product can be sold. You also need a Cosmetic Product Safety Report (CPSR) on file. ARIS can discuss how to coordinate this with an EU-based RP during the RFQ.
Is FDA approval required before selling lip makeup in the US?
No — FDA does not approve cosmetics before sale. Since MoCRA, however, brands must support facility registration, product listing, safety substantiation and adverse-event reporting. Plan for these post-launch duties rather than a pre-sale approval step.
Can one lip formula serve both the EU and the US?
Often yes, if you build against the more restrictive EU ingredient lists first and avoid the most-restricted colourants and fragrance ingredients. The biggest risk is locking shade colourants before checking both destination lists — that forces rework later.
What documents should my lip makeup factory provide?
Expect ingredient lists, a safety or compliance file, labelling guidance for each market, batch or testing documentation and certificates relevant to your destination. ARIS discusses the specific document set for EU and US launches during the RFQ.
Which market is cheaper to launch into for a private label brand?
Neither is clearly cheaper. The EU is more documentation-heavy up front (RP, CPSR, CPNP, translated labels) while the US is faster to launch but more compliance-heavy after launch. Cost depends more on your category, quantity and label complexity than on the market alone.
Need a lip makeup OEM/ODM quote?
Send ARIS Cosmetics your product category, target market, quantity and reference images. WhatsApp is the fastest first step; email and a full RFQ are available for detailed briefs.